<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.112112</article-id><article-id pub-id-type="publisher-id">ACM-40735</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210200000_17445391.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  血浆D-二聚体评估晚期胃癌疗效的临床价值
  Clinical Value of Plasma D-Dimer in Evaluating the Curative Effect of Advanced Gastric Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>丽丽</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>宋</surname><given-names>诗</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>美玲</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邱</surname><given-names>文生</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>日照市中心医院，山东 日照</addr-line></aff><aff id="aff2"><addr-line>青岛大学附属医院肿瘤科，山东 青岛；日照市中心医院，山东 日照</addr-line></aff><aff id="aff4"><addr-line>青岛大学附属医院肿瘤科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>02</month><year>2021</year></pub-date><volume>11</volume><issue>02</issue><fpage>787</fpage><lpage>793</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨血浆D-二聚体在评估晚期胃癌近期疗效中的临床价值。方法：选取2014年1月至2016年12月在我院住院治疗的IV期胃癌患者94例，研究患者血浆D-二聚体水平与一般临床特征的相关性，评估治疗前后血浆D-二聚体水平变化与疗效的相关性。结果：晚期胃癌的化疗有效组患者血浆D-二聚体水平降低，而无效组血浆D-二聚体水平升高，提示其在晚期胃癌评价疗效方面的价值，可以用于评估晚期胃癌的近期疗效。研究还发现，晚期胃癌D-二聚体值及治疗疗效也许与肿瘤的转移部位有相关性，但本研究样本数量有限，尚需进一步验证结论。结论：晚期胃癌血浆D-二聚体水平明显升高，且D-二聚体值及治疗疗效与肿瘤的转移部位有相关性，治疗前后血浆D-二聚体水平的变化可作为晚期胃癌近期疗效评估的依据。但本研究样本量偏少，所得出的结果可能存在偏倚，尚需进一步研究证实。
    Objective: To explore the clinical value of plasma D-dimer in assessing the short-term efficacy of advanced gastric cancer. Methods: The correlation between plasma D-dimer level and general clinical characteristics was studied in 94 IV gastric cancer patients hospitalized in our hospital from January 2014 to December 2016 and to evaluate the correlation between plasma D-dimer level and curative effect before and after treatment. Results: The plasma D-dimer level in the chemotherapy effective group of advanced gastric cancer decreased, while the plasma D-dimer level in the ineffective group increased, suggesting its value in evaluating the efficacy of advanced gastric cancer, which can be used to evaluate the short-term efficacy of advanced gastric cancer. D-dimer value and therapeutic efficacy of advanced gastric cancer may be related to the metastatic site of the tumor, but the number of samples in this study is limited, which needs further verification. Conclusion: The plasma D-dimer level of advanced gastric cancer is obviously increased, and the D-dimer value and therapeutic effect are related to the metastasis site of the tumor. The change of plasma D-dimer level before and after treatment can be used as the basis for the evaluation of the short-term curative effect of advanced gastric cancer. However, the sample size of this study is small, and the results may be biased, which needs further study and confirmation. 
  
 
</p></abstract><kwd-group><kwd>D-二聚体，胃癌，疗效评估, D-Dimer</kwd><kwd> Gastric Cancer</kwd><kwd> Evaluation of Efficacy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨血浆D-二聚体在评估晚期胃癌近期疗效中的临床价值。方法：选取2014年1月至2016年12月在我院住院治疗的IV期胃癌患者94例，研究患者血浆D-二聚体水平与一般临床特征的相关性，评估治疗前后血浆D-二聚体水平变化与疗效的相关性。结果：晚期胃癌的化疗有效组患者血浆D-二聚体水平降低，而无效组血浆D-二聚体水平升高，提示其在晚期胃癌评价疗效方面的价值，可以用于评估晚期胃癌的近期疗效。研究还发现，晚期胃癌D-二聚体值及治疗疗效也许与肿瘤的转移部位有相关性，但本研究样本数量有限，尚需进一步验证结论。结论：晚期胃癌血浆D-二聚体水平明显升高，且D-二聚体值及治疗疗效与肿瘤的转移部位有相关性，治疗前后血浆D-二聚体水平的变化可作为晚期胃癌近期疗效评估的依据。但本研究样本量偏少，所得出的结果可能存在偏倚，尚需进一步研究证实。</p></sec><sec id="s2"><title>关键词</title><p>D-二聚体，胃癌，疗效评估</p></sec><sec id="s3"><title>Clinical Value of Plasma D-Dimer in Evaluating the Curative Effect of Advanced Gastric Cancer<sup> </sup></title><p>Lili Wang<sup>1,2</sup>, Shi Song<sup>2</sup>, Meiling Zhang<sup>2</sup>, Wensheng Qiu<sup>1*</sup></p><p><sup>1</sup>Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><sup>2</sup>The Central Hospital of Rizhao, Rizhao Shandong</p><p><img src="//html.hanspub.org/file/51-1571919x4_hanspub.png" /></p><p>Received: Jan. 25<sup>th</sup>, 2021; accepted: Feb. 9<sup>th</sup>, 2021; published: Feb. 26<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/51-1571919x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the clinical value of plasma D-dimer in assessing the short-term efficacy of advanced gastric cancer. Methods: The correlation between plasma D-dimer level and general clinical characteristics was studied in 94 IV gastric cancer patients hospitalized in our hospital from January 2014 to December 2016 and to evaluate the correlation between plasma D-dimer level and curative effect before and after treatment. Results: The plasma D-dimer level in the chemotherapy effective group of advanced gastric cancer decreased, while the plasma D-dimer level in the ineffective group increased, suggesting its value in evaluating the efficacy of advanced gastric cancer, which can be used to evaluate the short-term efficacy of advanced gastric cancer. D-dimer value and therapeutic efficacy of advanced gastric cancer may be related to the metastatic site of the tumor, but the number of samples in this study is limited, which needs further verification. Conclusion: The plasma D-dimer level of advanced gastric cancer is obviously increased, and the D-dimer value and therapeutic effect are related to the metastasis site of the tumor. The change of plasma D-dimer level before and after treatment can be used as the basis for the evaluation of the short-term curative effect of advanced gastric cancer. However, the sample size of this study is small, and the results may be biased, which needs further study and confirmation.</p><p>Keywords:D-Dimer, Gastric Cancer, Evaluation of Efficacy</p><disp-formula id="hanspub.40735-formula78"><graphic xlink:href="//html.hanspub.org/file/51-1571919x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/51-1571919x8_hanspub.png" /> <img src="//html.hanspub.org/file/51-1571919x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>国际癌症研究机构(IARC)于2018年9月发布了2018年最新全球癌症数据统计：胃癌发病率占第五位，死亡率占第三位 [<xref ref-type="bibr" rid="hanspub.40735-ref1">1</xref>]。在中国，胃癌是最常见的消化道恶性肿瘤，晚期胃癌的占比和病死率均明显高于东亚其他胃癌高发国家。一项流行病学调查显示 [<xref ref-type="bibr" rid="hanspub.40735-ref2">2</xref>]，IV期胃癌所占比例约为40%，而同时期日本IV期胃癌所占比例仅为15%。诊断时间过晚加重了患者的疾病负担，对于这些病人，化疗是胃癌治疗中重要的手段之一。化疗疗效判断、复发转移的监测目前主要依靠影像学检查，影像学检查的不足之处为价格相对较高，存在电离辐射损伤等，而血液学检查特异标志物可作为临床评价的重要补充。但胃癌没有特异性高的预测疗效的生物标志物，故寻求灵敏的生物标志物来评估治疗效果，以此减轻病人经济负担有着重要意义。</p><p>相关研究已证明 [<xref ref-type="bibr" rid="hanspub.40735-ref3">3</xref>] 恶性肿瘤细胞能产生促凝物质，致使人体的凝血系统被激活，这种激活与肿瘤的进展、血管生成和转移扩散有关。本研究意在探讨D-二聚体在评估晚期胃癌患者治疗疗效中的价值。现将我院2014年1月~2016年12月收治的94例IV期胃癌患者，检测其化疗前后血浆中D-二聚体的含量，以观察其含量与肿瘤患者病情及化疗疗效的关系。现将详细情况总结以下：</p></sec><sec id="s6"><title>2. 材料和方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>本研究经医院伦理委员会审核并批准。选取2014年1月至2016年12月在我院住院治疗的IV期胃癌患者94例，男64例，女30例，年龄23~77岁。按照AJCC第八版胃癌分期标准进行分期，均为IV期晚期病人。所有患者均符合以下条件：① 全部患者有临床病理资料，病理证实为胃癌；② 初治患者，既往未行肿瘤方面治疗；③ 全部患者具有可测量的病灶；④ Karnofsky评分 ≥ 80分；⑤ 血常规及肝肾功能基本正常，无高血压、糖尿病、肾脏疾病、出血性、血栓及急慢性炎症等引起D-二聚体升高的合并疾病，未应用非甾体类抗炎药物及其他影响凝血功能的药物。</p></sec><sec id="s6_2"><title>2.2. 治疗方案</title><p>患者至少接受2周期的化疗，主要方案包括：(1) FOLFOX (奥沙利铂 + 5-FU + 亚叶酸钙)；(2) XELOX (奥沙利铂 + 卡培他滨)；(3) SOX (奥沙利铂 + 替吉奥)；(4) FLOT (多西他赛 + 奥沙利铂 + 5-FU + 亚叶酸钙)；(5) TP (紫杉类 + 顺铂)；(6) DX (多西他赛 + 卡培他滨)；(7) FP：(5-FU/卡培他滨 + 顺铂)；(8) 紫杉醇 + 替加氟/替吉奥方案；(9) DOX (多西他赛 + 奥沙利铂 + 卡培他滨)；(10) FOLFIRI (依立替康 + 5-FU + 亚叶酸钙)。所有方案及剂量选择都参考指南推荐，结合患者自身具体情况，由主治医师选择最适宜的治疗方案。</p></sec><sec id="s6_3"><title>2.3. 检测方法</title><p>D-二聚体采用CS-5100全自动凝血分析仪，应用免疫比浊法测其含量。CEA、CA19-9、CA72-4采用cobas 8000全自动生化免疫分析仪检测。正常参考值分别为：D-二聚体：0~500 ng/ml；CEA：0~5 ng/ml；CA199：0~27 U/ml；CA72-4：0~6.9 U/ml，检测结果超出正常参考值范围上限者为阳性。</p></sec><sec id="s6_4"><title>2.4. 疗效评价</title><p>在每次化疗前完善血浆D-二聚体、肿瘤标志物和影像学等检查，于化疗第3周期前评价疗效。根据2009年1月实体瘤治疗疗效评价标准1.1版(RECIST) [<xref ref-type="bibr" rid="hanspub.40735-ref3">3</xref>] 进行疗效评价。分为完全缓解(CR)、部分缓解(PR)、稳定(SD)和进展(PD)四部分，其中CR + PR评定为治疗有效组，SD + PD评定为治疗无效组。</p></sec><sec id="s6_5"><title>2.5. 统计学分析</title><p>釆用SPSS23.0软件进行统计分析。应用Pearson相关分析及采用卡方检验分析血浆D-二聚体与化疗疗效及一般临床特征的相关性；应用ROC曲线评价血浆D-二聚体化疗前后变化率对胃癌影像学客观疗效评价的检验效能。所有统计均采用双侧检验，以P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 临床特征</title><p>本研究共包含94例IV期胃癌患者，患者资料的临床特征，详见表1。</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Clinical features of 94 patients with stage IV gastric cance</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >临床特征</th><th align="center" valign="middle" >例数(%)</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >性别</td><td align="center" valign="middle" >男</td><td align="center" valign="middle" >64 (68.1)</td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >30 (31.9)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >年龄</td><td align="center" valign="middle" >小于等于65岁</td><td align="center" valign="middle" >67 (71.3)</td></tr><tr><td align="center" valign="middle" >大于65岁</td><td align="center" valign="middle" >27 (28.7)</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >HP感染</th><th align="center" valign="middle" >阳性</th><th align="center" valign="middle" >37 (39.4)</th></tr></thead><tr><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >57 (60.6)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >PS评分</td><td align="center" valign="middle" >0或1分</td><td align="center" valign="middle" >76 (80.9)</td></tr><tr><td align="center" valign="middle" >2分</td><td align="center" valign="middle" >18 (19.1)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >HER2表达</td><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >84 (89.4)</td></tr><tr><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >10 (10.6)</td></tr><tr><td align="center" valign="middle"  rowspan="6"  >病理分型</td><td align="center" valign="middle" >高分化腺癌</td><td align="center" valign="middle" >1 (1.1)</td></tr><tr><td align="center" valign="middle" >中分化腺癌</td><td align="center" valign="middle" >11 (11.7)</td></tr><tr><td align="center" valign="middle" >低分化腺癌</td><td align="center" valign="middle" >70 (74.5)</td></tr><tr><td align="center" valign="middle" >印戒细胞癌</td><td align="center" valign="middle" >10 (10.6)</td></tr><tr><td align="center" valign="middle" >神经内分泌癌</td><td align="center" valign="middle" >1 (1.1)</td></tr><tr><td align="center" valign="middle" >腺鳞癌</td><td align="center" valign="middle" >1 (1.1)</td></tr><tr><td align="center" valign="middle"  rowspan="5"  >原发部位</td><td align="center" valign="middle" >贲门</td><td align="center" valign="middle" >12 (12.8)</td></tr><tr><td align="center" valign="middle" >胃窦</td><td align="center" valign="middle" >45 (47.9)</td></tr><tr><td align="center" valign="middle" >胃体</td><td align="center" valign="middle" >28 (29.8)</td></tr><tr><td align="center" valign="middle" >胃底</td><td align="center" valign="middle" >7 (7.4)</td></tr><tr><td align="center" valign="middle" >幽门</td><td align="center" valign="middle" >2 (2.1)</td></tr><tr><td align="center" valign="middle"  rowspan="7"  >转移部位</td><td align="center" valign="middle" >淋巴结</td><td align="center" valign="middle" >35 (37.2)</td></tr><tr><td align="center" valign="middle" >腹腔积液</td><td align="center" valign="middle" >17 (18.1)</td></tr><tr><td align="center" valign="middle" >肝脏</td><td align="center" valign="middle" >25 (26.6)</td></tr><tr><td align="center" valign="middle" >肺</td><td align="center" valign="middle" >2 (2.1)</td></tr><tr><td align="center" valign="middle" >骨</td><td align="center" valign="middle" >7 (7.4)</td></tr><tr><td align="center" valign="middle" >卵巢</td><td align="center" valign="middle" >5 (5.3)</td></tr><tr><td align="center" valign="middle" >其它</td><td align="center" valign="middle" >3 (3.2)</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >疗效评估</td><td align="center" valign="middle" >CR + PR</td><td align="center" valign="middle" >55 (58.5)</td></tr><tr><td align="center" valign="middle" >SD</td><td align="center" valign="middle" >17 (18.1)</td></tr><tr><td align="center" valign="middle" >PD</td><td align="center" valign="middle" >22 (23.4)</td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. 94例IV期胃癌患者的临床特征</p></sec><sec id="s7_2"><title>3.2 一般临床特征在D-二聚体表达及有效组和无效组中的分布情况</title><p>94例晚期胃癌患者初诊时，血浆D-二聚体水平中位数为1205.06 ng/ml，较正常值明显升高。按D-二聚体水平中位数为界，分为D-二聚体高表达组(&gt;中位数)和D-二聚体低表达组(&lt;中位数)，D-二聚体高表达组有47例，D-二聚体低表达组有47例。患者2周期化疗后CR + PR评定为治疗有效组，SD + PD评定为治疗无效组。有效组55例，无效组39例。D-二聚体高表达组和D-二聚体低表达组，有效组和无效组在不同性别、年龄、HP感染、HER2表达、原发部位、病理分型的分布中没有明显差异(P &gt; 0.05)，但在转移部位的分布中有统计学差异(P &lt; 0.05)。可以表明晚期胃癌D-二聚体值及治疗疗效也许与肿瘤的转移部位有相关性。详见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The distribution of general clinical features in D-dimer expression, effective group and ineffective grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="3"   rowspan="2"  ></th><th align="center" valign="middle"  colspan="2"  >D二聚体</th><th align="center" valign="middle"  rowspan="2"  >X<sup>2 </sup></th><th align="center" valign="middle"  rowspan="2"  >P</th><th align="center" valign="middle"  colspan="2"  >分组</th><th align="center" valign="middle"  rowspan="2"  >X<sup>2</sup></th><th align="center" valign="middle"  rowspan="2"  >P</th></tr></thead><tr><td align="center" valign="middle" >高表达</td><td align="center" valign="middle" >低表达</td><td align="center" valign="middle" >有效组</td><td align="center" valign="middle" >无效组</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >性别</td><td align="center" valign="middle"  colspan="2"  >男</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >33</td><td align="center" valign="middle"  rowspan="2"  >0.196</td><td align="center" valign="middle"  rowspan="2"  >0.658</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" >28</td><td align="center" valign="middle"  rowspan="2"  >0.422</td><td align="center" valign="middle"  rowspan="2"  >0.516</td></tr><tr><td align="center" valign="middle"  colspan="2"  >女</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >11</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >年龄</td><td align="center" valign="middle"  colspan="2"  >≤65</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >29</td><td align="center" valign="middle"  rowspan="2"  >3.326</td><td align="center" valign="middle"  rowspan="2"  >0.068</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >1.676</td><td align="center" valign="middle" >0.196</td></tr><tr><td align="center" valign="middle"  colspan="2"  >&gt;65</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >HP感染</td><td align="center" valign="middle"  colspan="2"  >阳性</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >19</td><td align="center" valign="middle"  rowspan="2"  >0.045</td><td align="center" valign="middle"  rowspan="2"  >0.833</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >15</td><td align="center" valign="middle"  rowspan="2"  >0.023</td><td align="center" valign="middle"  rowspan="2"  >0.080</td></tr><tr><td align="center" valign="middle"  colspan="2"  >阴性</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" >24</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >HER2表达</td><td align="center" valign="middle"  colspan="2"  >阳性</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >9</td><td align="center" valign="middle"  rowspan="2"  >7.162</td><td align="center" valign="middle"  rowspan="2"  >0.102</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >7</td><td align="center" valign="middle"  rowspan="2"  >3.474</td><td align="center" valign="middle"  rowspan="2"  >0.053</td></tr><tr><td align="center" valign="middle"  colspan="2"  >阴性</td><td align="center" valign="middle" >46</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >52</td><td align="center" valign="middle" >32</td></tr><tr><td align="center" valign="middle"  rowspan="6"  >病理分型</td><td align="center" valign="middle"  rowspan="3"  >腺癌</td><td align="center" valign="middle" >高</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle"  rowspan="6"  >3.491</td><td align="center" valign="middle"  rowspan="6"  >0.625</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0</td><td align="center" valign="middle"  rowspan="6"  >5.894</td><td align="center" valign="middle"  rowspan="6"  >0.317</td></tr><tr><td align="center" valign="middle" >中</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >7</td></tr><tr><td align="center" valign="middle" >低</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >44</td><td align="center" valign="middle" >26</td></tr><tr><td align="center" valign="middle"  colspan="2"  >印戒细胞癌</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >5</td></tr><tr><td align="center" valign="middle"  colspan="2"  >神经内分泌癌</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle"  colspan="2"  >腺鳞癌</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle"  rowspan="5"  >原发部位</td><td align="center" valign="middle"  colspan="2"  >贲门</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >11</td><td align="center" valign="middle"  rowspan="5"  >13.46</td><td align="center" valign="middle"  rowspan="5"  >0.059</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >6</td><td align="center" valign="middle"  rowspan="5"  >1.436</td><td align="center" valign="middle"  rowspan="5"  >0.838</td></tr><tr><td align="center" valign="middle"  colspan="2"  >胃窦</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >17</td></tr><tr><td align="center" valign="middle"  colspan="2"  >胃体</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >11</td></tr><tr><td align="center" valign="middle"  colspan="2"  >胃底</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >4</td></tr><tr><td align="center" valign="middle"  colspan="2"  >幽门</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle"  rowspan="7"  >转移部位</td><td align="center" valign="middle"  colspan="2"  >淋巴结</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >21</td><td align="center" valign="middle"  rowspan="7"  >14.99</td><td align="center" valign="middle"  rowspan="7"  >0.020</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >19</td><td align="center" valign="middle"  rowspan="7"  >13.076</td><td align="center" valign="middle"  rowspan="7"  >0.042</td></tr><tr><td align="center" valign="middle"  colspan="2"  >腹腔积液</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >8</td></tr><tr><td align="center" valign="middle"  colspan="2"  >肝脏</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >5</td></tr><tr><td align="center" valign="middle"  colspan="2"  >肺</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle"  colspan="2"  >骨</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle"  colspan="2"  >卵巢</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle"  colspan="2"  >其它</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2</td></tr></tbody></table></table-wrap><p>表2. 一般临床特征在D-二聚体表达及有效组和无效组中的分布情况</p></sec><sec id="s7_3"><title>3.3. 化疗前后血浆D-二聚体水平与胃癌疗效的相关性</title><p>94例胃癌患者的有效组和无效组中，化疗前后血浆D-二聚体水平的差异均有统计学意义，可以认为化疗有效时，化疗前后血浆D-二聚体水平较前下降(P &lt; 0.05)；化疗无效时，化疗前后血浆D-二聚体水平较前上升(P &lt; 0.05)。详见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Correlation between plasma D-dimer level before and after chemotherapy and curative effect of patients with advanced gastric cance</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >疗效</th><th align="center" valign="middle" >化疗前水平</th><th align="center" valign="middle" >r</th><th align="center" valign="middle" >p</th><th align="center" valign="middle" >化疗后水平</th><th align="center" valign="middle" >r</th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >D二聚体</td><td align="center" valign="middle" >有效</td><td align="center" valign="middle" >2464.34</td><td align="center" valign="middle"  rowspan="2"  >−0.256</td><td align="center" valign="middle"  rowspan="2"  >0.013</td><td align="center" valign="middle" >1570.22</td><td align="center" valign="middle"  rowspan="2"  >0.232</td><td align="center" valign="middle"  rowspan="2"  >0.045</td></tr><tr><td align="center" valign="middle" >无效</td><td align="center" valign="middle" >1342.81</td><td align="center" valign="middle" >1831.71</td></tr></tbody></table></table-wrap><p>表3. 化疗前后血浆D-二聚体水平与晚期胃癌患者疗效的相关性</p></sec><sec id="s7_4"><title>3.4. 血浆D-二聚体化疗前后变化率与化疗疗效的相关性</title><p>经单样本Kolmogorov-Smirnov检验，化疗前后血浆D-二聚体变化率均呈偏态分布(P &lt; 0.05)。Spearman 秩相关分析结果提示，2个周期化疗后D-二聚体变化率与化疗疗效(CR + PR, SD, PD)存在相关关系(rD-二聚体 = 0.695，P = 0.001)，见表4。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Correlation between the change rate of plasma D-dimer before and after chemotherapy and the curative effect of chemotherap</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >疗效</th><th align="center" valign="middle" >变化率%</th><th align="center" valign="middle" >r</th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle"  rowspan="3"  >D二聚体</td><td align="center" valign="middle" >CR + PR</td><td align="center" valign="middle" >−47.03</td><td align="center" valign="middle"  rowspan="3"  >0.695</td><td align="center" valign="middle"  rowspan="3"  >0.001</td></tr><tr><td align="center" valign="middle" >SD</td><td align="center" valign="middle" >−3.76</td></tr><tr><td align="center" valign="middle" >PD</td><td align="center" valign="middle" >78.71</td></tr></tbody></table></table-wrap><p>表4. 血浆D-二聚体化疗前后变化率与化疗疗效的相关性</p></sec><sec id="s7_5"><title>3.5. ROC曲线评价D-二聚体化疗前后变化率在预测近期疗效中的应用</title><p>以化疗疗效为有效(OR)作为阳性预测结果，以灵敏度为纵坐标，以1-特异度为横坐标分别做2周期化疗前后血浆D二聚体变化率对晚期胃癌疗效检测的ROC曲线图，结果提示：血浆D二聚体变化率可以有效的评价晚期胃癌化疗是否达到OR，绘制的ROC曲线下面积分别为：0.885 (95%CI：0.810~0.959)，P<sub>D-</sub><sub>二聚体</sub> = 0.038；详见图1。Youden指数最大时，血浆D-二聚体变化率截点为−7.49%，灵敏度69.2%，特异度58.2%，即化疗后血浆D-二聚体下降 ≥ 7.49%时，可以判断胃癌化疗有效。</p><p>图1. 第2周期化疗后血浆D-二聚体变化率对晚期胃癌疗效检测的ROC曲线</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>多项研究证明 [<xref ref-type="bibr" rid="hanspub.40735-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.40735-ref5">5</xref>]，恶性肿瘤患者特别是晚期肿瘤病人，机体高凝状态加重，继发性纤溶系统会进一步亢进，D-二聚体为交联纤维蛋白经纤溶酶作用后的一种终末产物，是机体纤溶亢进与高凝状态的分子标志物，是临床中直接反映体内纤溶酶与凝血酶生成的指标，血浆D-二聚体水平升高反映了机体继发性纤溶活性增强 [<xref ref-type="bibr" rid="hanspub.40735-ref6">6</xref>]。在恶性肿瘤的发展过程中纤维形成和溶解持续发展，D-二聚体作为分子标志物其浓度与病情变化呈正相关系。多项研究表明 [<xref ref-type="bibr" rid="hanspub.40735-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.40735-ref8">8</xref>] 恶性肿瘤患者血浆D-二聚体值与肿瘤的发生、发展、分期和治疗效果有相关性。闫华等 [<xref ref-type="bibr" rid="hanspub.40735-ref9">9</xref>] 研究也发现恶性肿瘤患者中，化疗有效的患者体内血浆D-二聚体含量水平会有所下降，这表明凝血–纤溶系统功能紊乱的现象得到了纠正。本研究结果显示，晚期胃癌血浆D-二聚体水平明显升高，D-二聚体值及治疗疗效与肿瘤的转移部位有相关性。晚期胃癌的化疗有效组患者血浆D-二聚体水平降低，而无效组血浆D-二聚体水平升高，提示其在晚期胃癌评价疗效方面具有一定临床应用和研究价值，可以用于评估晚期胃癌的治疗疗效。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，晚期胃癌血浆D-二聚体水平明显升高，且D-二聚体值及治疗疗效与肿瘤的转移部位有相关性，治疗前后血浆D-二聚体水平的变化可作为晚期胃癌近期疗效评估的依据。但本研究样本量偏少，所得出的结果可能存在偏倚，尚需进一步研究证实。</p></sec><sec id="s10"><title>文章引用</title><p>王丽丽,宋 诗,张美玲,邱文生. 血浆D-二聚体评估晚期胃癌疗效的临床价值Clinical Value of Plasma D-Dimer in Evaluating the Curative Effect of Advanced Gastric Cancer[J]. 临床医学进展, 2021, 11(02): 787-793. https://doi.org/10.12677/ACM.2021.112112</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40735-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">International Agency for Research on Cancer (2018) Latest Global Cancer Data: Cancer Burden Rises to 18.1 Million New Cases and 9.6 Million Cancer Deaths in 2018.</mixed-citation></ref><ref id="hanspub.40735-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">郑潇豪, 解亦斌. 中国晚期胃癌的诊疗现状[J]. 癌症进展, 2019, 17(1): 13-17.</mixed-citation></ref><ref id="hanspub.40735-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Voland, C., Serre, C.M. and Delmas, P. (2000) Platelet-Osteosareoma Cell Interaction Is Mediated through a Specific Fibrinogen-Binding Sequence Located within the N-Terminal Domain of Thrombospond in 1. Journal of Bone and Mineral Research, 15, 361-368. &lt;br&gt;https://doi.org/10.1359/jbmr.2000.15.2.361</mixed-citation></ref><ref id="hanspub.40735-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Falang, A., Marchetti, M. and Vignoli, A. (2013) Coagulation and Cancer: Biological and Clinical Aspects. Journal of Thrombosis and Haemostasis, 11, 223-233. &lt;br&gt;https://doi.org/10.1111/jth.12075</mixed-citation></ref><ref id="hanspub.40735-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">王莉, 刘霞. 恶性肿瘤病人血浆D-二聚体和FDP检测的临床意义探讨[J]. 成都医学院学报, 2012, 7(2): 117.</mixed-citation></ref><ref id="hanspub.40735-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">李丹丹, 马聪. D-二聚体检测的临床应用进展[J]. 血栓与止血学, 2011, 17(3): 138-141.</mixed-citation></ref><ref id="hanspub.40735-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">赵晶, 姜达. 恶性肿瘤高凝状态及其干预[J]. 癌症进展, 2013, 11(1): 48-52.</mixed-citation></ref><ref id="hanspub.40735-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">刘志荣. 胃癌与D-二聚体含量的关系研究[J]. 山西医药杂志, 2012, 41(4): 384-385.</mixed-citation></ref><ref id="hanspub.40735-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">闫华, 赵崇高, 江涛. 恶性肿瘤患者血浆D-二聚体和纤维蛋白原水平的检测与分析[J]. 河南科技大学学报(医学版), 2007, 25(1): 27-28.</mixed-citation></ref></ref-list></back></article>